Merck & Co Expands C Diff Franchise With US Zinplava Approval

Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.

The US FDA has approved Merck & Co. Inc.’s Zinplava (bezlotoxumab) for reducing the recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.

The product is an antibody therapy targeted against a toxin produced by the bacterium, known as toxin B, that causes...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip